Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Jun;59(6):943–947. doi: 10.1038/bjc.1989.200

Ki67 immunostaining in primary breast cancer: pathological and clinical associations.

N Bouzubar 1, K J Walker 1, K Griffiths 1, I O Ellis 1, C W Elston 1, J F Robertson 1, R W Blamey 1, R I Nicholson 1
PMCID: PMC2246720  PMID: 2472168

Abstract

Ki67 immunostaining has been performed on 136 primary breast cancers and related to various clinical and pathological features of the disease. Staining was most frequently seen in poorly differentiated tumours showing high rates of mitotic activity, but was independent of tumour size, lymph-node status and ER expression. A high level of Ki67 immunostaining was often associated with early recurrence of breast cancer after mastectomy. These data are consistent with the concept of the Ki67 antibody detecting an antigen that is closely related to cell proliferation and thus provides a clinically useful marker for this important characteristic of the tumour.

Full text

PDF
943

Images in this article

944Figure 1
on p.944

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baisch H., Gerdes J. Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki-67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet. 1987 Jul;20(4):387–391. doi: 10.1111/j.1365-2184.1987.tb01323.x. [DOI] [PubMed] [Google Scholar]
  2. Barnard N. J., Hall P. A., Lemoine N. R., Kadar N. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol. 1987 Aug;152(4):287–295. doi: 10.1002/path.1711520407. [DOI] [PubMed] [Google Scholar]
  3. Blamey R. W., Bishop H. M., Blake J. R., Doyle P. J., Elston C. W., Haybittle J. L., Nicholson R. I., Griffiths K. Relationship between primary breast tumor receptor status and patient survival. Cancer. 1980 Dec 15;46(12 Suppl):2765–2769. doi: 10.1002/1097-0142(19801215)46:12+<2765::aid-cncr2820461404>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  4. Cooke T. The clinical application of oestrogen receptor analysis in early cancer of the breast. Ann R Coll Surg Engl. 1982 May;64(3):165–170. [PMC free article] [PubMed] [Google Scholar]
  5. Gerdes J., Dallenbach F., Lennert K., Lemke H., Stein H. Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol. 1984 Oct-Dec;2(4):365–371. doi: 10.1002/hon.2900020406. [DOI] [PubMed] [Google Scholar]
  6. Gerdes J., Lelle R. J., Pickartz H., Heidenreich W., Schwarting R., Kurtsiefer L., Stauch G., Stein H. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol. 1986 Sep;39(9):977–980. doi: 10.1136/jcp.39.9.977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gerdes J., Lemke H., Baisch H., Wacker H. H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed] [Google Scholar]
  8. Haag D., Goerttler K., Tschahargane C. The proliferative index (PI) of human breast cancer as obtained by flow cytometry. Pathol Res Pract. 1984 Mar;178(4):315–322. doi: 10.1016/S0344-0338(84)80020-5. [DOI] [PubMed] [Google Scholar]
  9. Haybittle J. L., Blamey R. W., Elston C. W., Johnson J., Doyle P. J., Campbell F. C., Nicholson R. I., Griffiths K. A prognostic index in primary breast cancer. Br J Cancer. 1982 Mar;45(3):361–366. doi: 10.1038/bjc.1982.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lellé R. J., Heidenreich W., Stauch G., Gerdes J. The correlation of growth fractions with histologic grading and lymph node status in human mammary carcinoma. Cancer. 1987 Jan 1;59(1):83–88. doi: 10.1002/1097-0142(19870101)59:1<83::aid-cncr2820590119>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  11. Meyer J. S., Lee J. Y. Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res. 1980 Jun;40(6):1890–1896. [PubMed] [Google Scholar]
  12. Silvestrini R., Sanfilippo O., Tedesco G. Kinetics of human mammary carcinomas and their correlation with the cancer and the host characteristics. Cancer. 1974 Oct;34(4):1252–1258. doi: 10.1002/1097-0142(197410)34:4<1252::aid-cncr2820340435>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  13. Tubiana M., Pejovic M. J., Renaud A., Contesso G., Chavaudra N., Gioanni J., Malaise E. P. Kinetic parameters and the course of the disease in breast cancer. Cancer. 1981 Mar 1;47(5):937–943. doi: 10.1002/1097-0142(19810301)47:5<937::aid-cncr2820470520>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  14. Valeriote F., van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res. 1975 Oct;35(10):2619–2630. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES